Global Brain Imaging Modalities Market - A Global and Regional Analysis: Focus on Product Type, Patient Age, End User, and Regional Analysis - Analysis and Forecast, 2022-2031
Market Report Coverage - Brain Imaging Modalities
Market Segmentation
- Product - CT Devices, MRI Devices, PET Devices, PET-CT Devices and PET-MRI Devices
- Patient Type - Adults and Pediatrics and Infants
- End User - Hospitals and Clinics, Diagnostic Imaging Centers, and Ambulatory Surgical Centers
- North America - U.S. and Canada
- Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
- Asia-Pacific - Japan, China, South Korea, India, Australia and New Zealand, and Rest-of-Asia-Pacific
- Rest-of-the-World - Latin America, and Middle East and Africa
- Rising Prevalence of Neurological Disorders and Traumatic Brain Injuries (TBI)
- Technological Advancements in the Brain Imaging Modalities and Systems
- Growing Popularity of Molecular Imaging in Brain Imaging
- Hospital Budget Cuts and High Upfront Cost
- Declining Helium Availability
- Integration of Imaging Systems and Software with Novel Biomarkers
Aspect Imaging, Canon, Inc., Esaote SpA, Fujifilm Holdings Corporation, General Electric Company, Hyperfine Inc., Koninklijke Philips N.V., Mediso Medical Imaging Systems, MinFound Medical Systems Co., Ltd., Samsung Electronics Co., Ltd., Shenzhen Anke High-Tech Co.,Ltd., Shimadzu Corporation, Siemens Healthineers AG, United Imaging Healthcare Co., Ltd., VUNO Co., Ltd.
How This Report Can Add Value
Assuming that the reader is a manufacturer of brain imaging modalities, the report will assist them in the following ways:
- Understand their position compared to other key players in the market
- Stay updated with novel technology integration, features, and the latest developments in the market
- Understand the impact of COVID-19 on brain imaging and the entry barriers for new companies
- Gain insights into end-user perception concerning the brain imaging modalities market
- Identify some key players in the market and understand their valuable contribution
- How has COVID-19 impacted the growth of the global brain imaging modalities market?
- What are the key regulations governing the brain imaging modalities market in key regions?
- What technological developments are projected to have the maximum influence on the global brain imaging modalities market?
- Who are the leading players holding significant dominance in the global brain imaging modalities market?
- What are some of the growth opportunities which market players can capitalize on?
- What are the drivers and restraints for the global brain imaging modalities market?
- Which region has the highest growth rate in the brain imaging modalities market?
- Which are the fastest growing countries in terms of the global brain imaging modalities market?
- What are the key strategies being adopted by market players in the global brain imaging modalities market?
- Which are the emerging companies in the global brain imaging modalities market?
The global brain imaging modalities market is projected to witness significant growth during the forecast period 2022-2031. The high prevalence and growing incidences of brain diseases and neurogenerative disorders and the technological advancements in brain imaging modalities and systems are the key propellers for the growth of the market. Five key modalities of brain imaging modalities include computed tomography (CT) devices, magnetic resonance imaging (MRI) devices, positron emission tomography (PET) devices, PET-CT devices, and PET MRI devices. The field of cognitive neuroscience has emerged and developed rapidly over the last 20 years. To address the neural underpinnings of human cognition, this new field combines two traditionally separate disciplines, cognitive psychology and neurology.
The market for brain imaging modalities devices is rapidly growing, with an increasing number of modalities used in the imaging of various brain diseases and neurogenerative disorders (NDs). The high prevalence and growing incidences of neurological disorders (NDs) are one of the major factors augmenting the growth of the global brain imaging modalities market. Neurological diseases and mental disorders have emerged as serious public health concerns and substantial challenges to healthcare systems around the world. Genetic disorders, congenital anomalies or disorders, infections, lifestyle, or environmental health problems such as malnutrition, brain injury, spinal cord injury, or nerve injury are some of the causes of neurological problems.
The global brain imaging modalities market report highlights that the market was valued at $12,334.2 million in 2021 and is expected to reach $20,209.2 million by the end of 2031. The market is expected to grow at a CAGR of 5.06% during the forecast period 2022-2031.
Global Brain Imaging Modalities Market Drivers
Personalized and tailored treatment approaches based on monitoring and imaging findings and respecting pre-injury comorbidities and their therapies are warranted due to traumatic brain injury is a syndrome encompassing a variety of different affections to the brain, and since age-related comorbidities and treatments may also have a significant impact. More importantly, as the prevalence and incidence of neurological illnesses continue to rise, so will technological adoption. As a result, the growth of disease diagnosis and, as a result, the global market for brain imaging modalities will accelerate.
Governments invest a significant amount of money in healthcare insurance so that the overall healthcare costs can be reduced, and the quality of life and affordability of the treatment can be enhanced.
Global Brain Imaging Modalities Market Restraints
The factors restraining the growth of the global brain imaging devices market include the risks associated with radiation exposure and delay in regulatory approvals. Delay in regulatory approval for the products due to the stringent government regulations concerning the use of AI-enabled software in medical imaging hinders the market's growth. Moreover, another factor restraining the growth of the global brain imaging devices market is the high cost associated with medical imaging.
Global Brain Imaging Modalities Market Opportunities
High growth opportunities in emerging economies and the emergence of local companies in Asia-Pacific and the Middle East and Africa hold immense potential for the global brain imaging modalities market growth. In an era of machine learning and artificial intelligence, extracting quantitative biomarkers from medical images to aid illness detection, characterization, monitoring, and therapy response assessment is becoming increasingly desirable.
Impact of COVID-19 on the Global Brain Imaging Modalities Market
The COVID-19 pandemic had a debilitating impact on the global healthcare ecosystem. Hospitals and clinics faced several challenges such as lack of resources, high patient influx, and risk of infection among care providers. The market is projected to witness considerable growth during the forecast period 2021-2030. The increasing innovations and product designs in the global market and the growing use in emerging economies are the driving factors for the growth of the market.
Market Segmentation
Global Brain Imaging Modalities Market (by Product Type)
The global brain imaging modalities market, based on product type, has been segmented into CT devices, MRI devices, PET devices, PET-CT devices, and PET-MRI devices.
Global Brain Imaging Modalities Market (by Patient Type)
The global brain imaging modalities market, based on patient type, has been segmented into adults, and pediatrics and infants.
Global Brain Imaging Modalities Market (by End User)
The global brain imaging modalities market, based on end user, has been segmented into hospitals and clinics, diagnostic imaging centers, and ambulatory surgery centers surgical centers.
Hospitals and clinics are the major end users for the global brain imaging modalities market. The high volume of the end user makes them the primary diagnosis site for brain diseases and neurodegenerative disorders (NDs) in emerging economies. Furthermore, the adoption of brain imaging modalities in ASCs has been increased due to several factors such as personalized care to the patients and reduced recovery time.
Global Brain Imaging Modalities Market (by Region)
The different regions covered under the global brain imaging modalities market include North America, Europe, Asia-Pacific and Rest-of-the-World.
North America is expected to be the most lucrative region for the global brain imaging modalities market due to advanced healthcare infrastructure and a high focus on research and development activities. The Asia-Pacific brain imaging modalities market is one of the lucrative markets with immense potential for expansion by key players of the global brain imaging modalities market. The Asia-Pacific brain imaging modalities market is expected to grow at the fastest rate during the forecast period. This can be attributed to the massive geriatric population base, which is driving the increase in the volume of brain imaging modalities.
Key Market Players and Competition Synopsis
Some key players operating in the market include Aspect Imaging, Canon, Inc., Esaote SpA, Fujifilm Holdings Corporation, General Electric Company, Hyperfine Inc., Koninklijke Philips N.V., Mediso Medical Imaging Systems, MinFound Medical Systems Co., Ltd., Samsung Electronics Co., Ltd., Shenzhen Anke High-Tech Co.,Ltd., Shimadzu Corporation, Siemens Healthineers AG, United Imaging Healthcare Co., Ltd., and VUNO Co., Ltd.
Some strategies covered in this segment are funding activities, mergers and acquisitions (M&As), partnerships, alliances, business expansion, regulatory and legal activities, and new offerings.*PDF email from publisher allows for 1-3 users, withpermission to print*
Companies Mentioned
Aspect Imaging
Canon, Inc.
Esaote SpA
Fujifilm Holdings Corporation
General Electric Company
Hyperfine Inc.
Koninklijke Philips N.V.
Mediso Medical Imaging Systems
MinFound Medical Systems Co., Ltd.
Samsung Electronics Co., Ltd.
Shenzhen Anke High-Tech Co.,Ltd.
Shimadzu Corporation
Siemens Healthineers AG
United Imaging Healthcare Co., Ltd.
VUNO Co., Ltd.
- 1 Markets
- 1.1 Market Outlook
- 1.1.1 Product Definition
- 1.1.2 Inclusion and Exclusion Criteria
- 1.1.3 Key Findings
- 1.1.4 Market Growth Scenario
- 1.1.4.1 Realistic Growth
- 1.1.4.2 Optimistic Growth
- 1.1.4.3 Pessimistic/Conservative Growth
- 1.2 Industry Outlook
- 1.2.1 Technology Landscape
- 1.2.1.1 Key Trends
- 1.2.1.1.1 Integration of Hardware and Software Solutions for Imaging
- 1.2.1.1.2 Investigation of Ensemble Models that Involve Multiple Classifiers such as Biomarkers and Patient Features
- 1.2.1.1.3 Rising Preference for Portable Brain Scanners and Wearables
- 1.2.1.1.4 Integration of Augmented Reality with Medical Imaging
- 1.2.1.1.5 Increased Focus on Targeting the Pediatric Population
- 1.2.2 Opportunity Assessment
- 1.2.2.1 Short-Term Potential
- 1.2.2.2 Long-Term Potential
- 1.2.3 Product Benchmarking
- 1.2.4 Patent Analysis
- 1.2.4.1 Patent Analysis by Country/Cluster
- 1.2.4.2 Patent Analysis by Year
- 1.3 Impact of COVID-19 on the Global Brain Disease Modalities and Software Market
- 1.3.1 Impact on Facilities
- 1.3.2 Impact on Modalities Adoption
- 1.3.3 Impact on Market Size
- 1.3.3.1 Pre-COVID-19 Phase
- 1.3.3.2 During-COVID-19 Phase
- 1.3.3.3 Post-COVID-19 Phase
- 1.4 Business Dynamics
- 1.4.1 Impact Analysis
- 1.4.2 Business Drivers
- 1.4.2.1 Increasing Prevalence of Neurological Disorders
- 1.4.2.2 Rising AI Integration in the Field of Medical Imaging
- 1.4.2.3 Increasing Demand for Safer and Non-Invasive Devices for Medical Imaging
- 1.4.3 Business Restraints
- 1.4.3.1 High Upfront Cost of Imaging Devices
- 1.4.3.2 Declining Availability of Helium
- 1.4.4 Business Opportunities
- 1.4.4.1 Integration of Imaging Solutions with Novel Biomarkers to Enable Diagnosis of a Wider Range of Neurological Disorders
- 1.4.4.2 Integration of 3D Amplified MRI, a New Technological Advancement
- 2 Application
- 2.1 Brain Disease Modalities and Software Market (by Indication)
- 2.1.1 Opportunity Assessment
- 2.1.2 Growth Share Matrix
- 2.1.3 Brain Diseases
- 2.1.3.1 Patient Volume
- 2.1.3.2 Brain and Central Nervous System Cancer
- 2.1.3.2.1 Market Trend
- 2.1.3.2.2 Market Size and Forecast
- 2.1.3.2.3 Examination Process
- 2.1.3.2.4 Key Modalities Analysis
- 2.1.3.3 Idiopathic Epilepsy
- 2.1.3.3.1 Market Trend
- 2.1.3.3.2 Market Size and Forecast
- 2.1.3.3.3 Examination Process
- 2.1.3.3.4 Key Modalities Analysis
- 2.1.3.4 Ischemic Stroke
- 2.1.3.4.1 Market Trend
- 2.1.3.4.2 Market Size and Forecast
- 2.1.3.4.3 Examination Process
- 2.1.3.4.4 Key Modalities Analysis
- 2.1.3.5 Other Brain Diseases
- 2.1.3.5.1 Market Trend
- 2.1.3.5.2 Market Size and Forecast
- 2.1.3.5.3 Examination Process
- 2.1.3.5.4 Key Modalities Analysis
- 2.1.4 Neurodegenerative Diseases
- 2.1.4.1 Patient Volume
- 2.1.4.2 Key Examination Process for Disease Confirmation
- 2.1.4.3 Alzheimer’s Disease
- 2.1.4.3.1 Market Trend
- 2.1.4.3.2 Market Size and Forecast
- 2.1.4.3.3 Medical Bill and Fee
- 2.1.4.3.3.1 North America
- 2.1.4.3.3.2 Europe
- 2.1.4.3.3.3 Asia-Pacific
- 2.1.4.3.3.4 Rest-of-the-World
- 2.1.4.4 Multiple Sclerosis
- 2.1.4.4.1 Market Trend
- 2.1.4.4.2 Market Size and Forecast
- 2.1.4.4.3 Medical Bill and Fee
- 2.1.4.4.3.1 North America
- 2.1.4.4.3.2 Europe
- 2.1.4.4.3.3 Asia-Pacific
- 2.1.4.4.3.4 Rest-of-the-World
- 2.1.4.5 Parkinson’s Disease
- 2.1.4.5.1 Market Trend
- 2.1.4.5.2 Market Size and Forecast
- 2.1.4.5.3 Medical Bill and Fee
- 2.1.4.5.3.1 North America
- 2.1.4.5.3.2 Europe
- 2.1.4.5.3.3 Asia-Pacific
- 2.1.4.5.3.4 Rest-of-the-World
- 2.1.4.6 Motor Neuron Disease
- 2.1.4.6.1 Market Trend
- 2.1.4.6.2 Market Size and Forecast
- 2.1.4.6.3 Medical Bill and Fee
- 2.1.4.6.3.1 North America
- 2.1.4.6.3.2 Europe
- 2.1.4.6.3.3 Asia-Pacific
- 2.1.4.6.3.4 Rest-of-the-World
- 2.1.4.7 Other Neurodegenerative Diseases
- 2.1.4.7.1 Market Trend
- 2.1.4.7.2 Market Size and Forecast
- 2.1.4.7.3 Medical Bill and Fee
- 2.1.4.7.3.1 North America
- 2.1.4.7.3.2 Europe
- 2.1.4.7.3.3 Asia-Pacific
- 2.1.4.7.3.4 Rest-of-the-World
- 2.2 Global Brain Disease Modalities and Software Market (by Patient Type)
- 2.2.1 Opportunity Assessment
- 2.2.2 Adults
- 2.2.2.1 Market Trends
- 2.2.2.2 Market Size and Forecast
- 2.2.3 Pediatrics and Infants
- 2.2.3.1 Market Trends
- 2.2.3.2 Market Size and Forecast
- 2.3 Global Brain Disease Modalities and Software Market (by End User)
- 2.3.1 Opportunity Assessment
- 2.3.2 Hospitals and Clinics
- 2.3.3 Diagnostic Imaging Centers
- 2.3.4 Ambulatory Surgery Centers
- 3 Products
- 3.1 Brain Disease Modalities and Software Market (by Product)
- 3.1.1 Opportunity Assessment
- 3.1.2 Growth Share Matrix
- 3.1.3 Brain Modalities
- 3.1.3.1 Market Size and Forecast
- 3.1.3.2 by Type
- 3.1.3.2.1 PET Devices
- 3.1.3.2.2 PET-CT
- 3.1.3.2.3 PET-MRI
- 3.1.3.2.4 CT Devices
- 3.1.3.2.5 MRI Devices
- 3.1.4 Brain Analysis Software
- 3.1.4.1 Market Trends
- 3.1.4.1.1 North America
- 3.1.4.1.2 Europe
- 3.1.4.1.3 Asia-Pacific
- 3.1.4.1.4 Rest-of-the-World
- 3.1.4.2 Pricing Analysis
- 3.1.4.3 Vendor Trends
- 3.1.4.3.1 Market Share Analysis
- 3.1.4.3.2 Skills Analysis
- 3.1.4.3.3 Purpose/Application Analysis
- 3.1.4.3.4 Target Disease Analysis
- 3.1.4.3.5 Modality Analysis
- 3.1.4.3.6 Analytical Report Status
- 3.1.4.3.7 Regulatory Status Analysis
- 4 Region
- 4.1 North America Brain Disease Modalities and Software Market
- 4.1.1 Market
- 4.1.1.1 Regulatory Framework
- 4.1.1.2 Opportunity Assessment
- 4.1.1.3 Market Dynamics
- 4.1.1.3.1 Impact Analysis
- 4.1.1.4 Sizing and Forecast Analysis
- 4.1.2 Application
- 4.1.2.1 North America Brain Disease Modalities and Software Market (by Indication)
- 4.1.2.2 North America Brain Disease Modalities and Software Market (by Patient Type)
- 4.1.2.3 North America Brain Disease Modalities and Software Market (by End User)
- 4.1.3 Product
- 4.1.3.1 North America Brain Disease Modalities and Software Market (by Product)
- 4.1.4 North America Brain Disease Modalities and Software Market (by Country)
- 4.1.4.1 U.S.
- 4.1.4.2 Canada
- 4.2 Europe Brain Disease Modalities and Software Market
- 4.2.1 Market
- 4.2.1.1 Regulatory Framework
- 4.2.1.2 Opportunity Assessment
- 4.2.1.3 Market Dynamics
- 4.2.1.3.1 Impact Analysis
- 4.2.1.4 Sizing and Forecast Analysis
- 4.2.2 Application
- 4.2.2.1 Europe Brain Disease Modalities and Software Market (by Indication)
- 4.2.2.2 Europe Brain Disease Modalities and Software Market (by Patient Type)
- 4.2.2.3 Europe Brain Disease Modalities and Software Market (by End User)
- 4.2.3 Product
- 4.2.3.1 Europe Brain Disease Modalities and Software Market (by Product)
- 4.2.4 Europe Brain Disease Modalities and Software Market (by Country)
- 4.2.4.1 Germany
- 4.2.4.2 U.K.
- 4.2.4.3 France
- 4.2.4.4 Italy
- 4.2.4.5 Spain
- 4.2.4.6 Rest-of-Europe
- 4.3 Asia-Pacific Brain Disease Modalities and Software Market
- 4.3.1 Market
- 4.3.1.1 Regulatory Framework
- 4.3.1.2 Opportunity Assessment
- 4.3.1.3 Market Dynamics
- 4.3.1.3.1 Impact Analysis
- 4.3.1.4 Sizing and Forecast Analysis
- 4.3.2 Application
- 4.3.2.1 Asia-Pacific Brain Disease Modalities and Software Market (by Indication)
- 4.3.2.2 Asia-Pacific Brain Disease Modalities and Software Market (by Patient Type)
- 4.3.2.3 Asia-Pacific Brain Disease Modalities and Software Market (by End User)
- 4.3.3 Product
- 4.3.3.1 Asia-Pacific Brain Disease Modalities and Software Market (by Product)
- 4.3.4 Asia-Pacific Brain Disease Modalities and Software Market (by Country)
- 4.3.4.1 Japan
- 4.3.4.2 China
- 4.3.4.3 India
- 4.3.4.4 South Korea
- 4.3.4.5 Australia and New Zealand
- 4.3.4.6 Rest-of-Asia-Pacific
- 4.4 Rest-of-the-World Brain Disease Modalities and Software Market
- 4.4.1 Market
- 4.4.1.1 Regulatory Framework
- 4.4.1.2 Opportunity Assessment
- 4.4.1.3 Market Dynamics
- 4.4.1.3.1 Impact Analysis
- 4.4.1.4 Sizing and Forecast Analysis
- 4.4.2 Application
- 4.4.2.1 Rest-of-the-World Brain Disease Modalities and Software Market (by Indication)
- 4.4.2.2 Rest-of-the-World Brain Disease Modalities and Software Market (by Patient Type)
- 4.4.2.3 Rest-of-the-World Brain Disease Modalities and Software Market (by End User)
- 4.4.3 Product
- 4.4.3.1 Rest-of-the-World Brain Disease Modalities and Software Market (by Product)
- 4.4.4 Rest-of-the-World Brain Disease Modalities and Software Market (by Region)
- 4.4.4.1 Latin America
- 4.4.4.2 Middle East and Africa
- 5 Markets - Competitive Benchmarking & Company Profiles
- 5.1 Competitive Benchmarking and Company Profiles
- 5.1.1 Competitive Landscape
- 5.1.1.1 Key Strategies and Developments
- 5.1.1.1.1 Partnerships, Alliances, and Business Expansions
- 5.1.1.1.2 Funding Activities
- 5.1.1.1.3 New Offerings
- 5.1.1.1.4 Mergers and Acquisitions
- 5.1.1.1.5 Regulatory and Legal Activities
- 5.2 Market Share Analysis
- 5.3 Company Profiles
- 5.3.1 Brain Disease Modalities and Software Companies
- 5.3.1.1 United Imaging Healthcare Co., Ltd.
- 5.3.1.1.1 Company Overview
- 5.3.1.1.2 Role of United Imaging Healthcare Co., Ltd. in the Global Brain Disease Modalities and Software Market
- 5.3.1.1.3 Product Portfolio and Offerings
- 5.3.1.1.4 Recent Developments
- 5.3.1.1.5 SWOT Analysis
- 5.3.1.2 Koninklijke Philips N.V.
- 5.3.1.2.1 Company Overview
- 5.3.1.2.2 Role of Koninklijke Philips N.V. in the Global Brain Disease Modalities and Software Market
- 5.3.1.2.3 Product Portfolio and Offerings
- 5.3.1.2.4 Financials
- 5.3.1.2.5 SWOT Analysis
- 5.3.1.3 General Electric Company
- 5.3.1.3.1 Company Overview
- 5.3.1.3.2 Role of General Electric Company in the Global Brain Disease Modalities and Software Market
- 5.3.1.3.3 Product Portfolio and Offerings
- 5.3.1.3.4 Financials
- 5.3.1.3.5 SWOT Analysis
- 5.3.1.4 Canon, Inc.
- 5.3.1.4.1 Company Overview
- 5.3.1.4.2 Role of Canon, Inc. in the Global Brain Disease Modalities and Software Market
- 5.3.1.4.3 Product Portfolio and Offerings
- 5.3.1.4.4 Recent Developments
- 5.3.1.4.5 Financials
- 5.3.1.4.6 SWOT Analysis
- 5.3.1.5 Siemens Healthineers AG
- 5.3.1.5.1 Company Overview
- 5.3.1.5.2 Role of Siemens Healthineers AG in the Global Brain Disease Modalities and Software Market
- 5.3.1.5.3 Product Portfolio and Offerings
- 5.3.1.5.4 Financials
- 5.3.1.5.5 Recent Developments
- 5.3.1.5.6 SWOT Analysis
- 5.3.1.6 Vuno Co., Ltd.
- 5.3.1.6.1 Company Overview
- 5.3.1.6.2 Role of Vuno Co., Ltd. in the Global Brain Disease Modalities and Software Market
- 5.3.1.6.3 Product Portfolio and Offerings
- 5.3.1.6.4 Recent Developments
- 5.3.1.6.5 SWOT Analysis
- 5.3.1.7 Fujifilm Holdings Corporation
- 5.3.1.7.1 Company Overview
- 5.3.1.7.2 Role of Fujifilm Holdings Corporation in the Global Brain Disease Modalities and Software Market
- 5.3.1.7.3 Product Portfolio
- 5.3.1.7.4 Financials
- 5.3.1.7.5 Recent Developments
- 5.3.1.7.6 SWOT Analysis
- 5.3.1.8 Aspect Imaging
- 5.3.1.8.1 Company Overview
- 5.3.1.8.2 Role of Aspect Imaging in the Global Brain Disease Modalities and Software Market
- 5.3.1.8.3 Product Portfolio and Offerings
- 5.3.1.8.4 SWOT Analysis
- 5.3.2 Brain Imaging Software Companies
- 5.3.2.1 IXICO
- 5.3.2.1.1 Company Overview
- 5.3.2.1.2 Role of IXICO in the Global Brain Disease Modalities and Software Market
- 5.3.2.1.3 Product Portfolio and Offerings
- 5.3.2.1.4 Financials
- 5.3.2.1.5 Recent Developments
- 5.3.2.1.6 SWOT Analysis
- 5.3.2.2 QMENTA
- 5.3.2.2.1 Company Overview
- 5.3.2.2.2 Role of QMENTA in the Global Brain Disease Modalities and Software Market
- 5.3.2.2.3 Product Portfolio and Offerings
- 5.3.2.2.4 SWOT Analysis
- 5.3.2.3 Cortechs.ai
- 5.3.2.3.1 Company Overview
- 5.3.2.3.2 Role of Cortechs.ai in the Global Brain Disease Modalities and Software Market
- 5.3.2.3.3 Product Portfolio and Offerings
- 5.3.2.3.4 Recent Developments
- 5.3.2.3.5 SWOT Analysis
- 5.3.2.4 Quantib
- 5.3.2.4.1 Company Overview
- 5.3.2.4.2 Role of Quantib in the Global Brain Disease Modalities and Software Market
- 5.3.2.4.3 Product Portfolio and Offerings
- 5.3.2.4.4 Recent Developments
- 5.3.2.4.5 SWOT Analysis
- 5.3.2.5 Brainomix
- 5.3.2.5.1 Company Overview
- 5.3.2.5.2 Role of Brainomix in the Global Brain Disease Modalities and Software Market
- 5.3.2.5.3 Product Portfolio and Offerings
- 5.3.2.5.4 Recent Developments
- 5.3.2.5.5 SWOT Analysis
- 5.3.2.6 Qure.AI
- 5.3.2.6.1 Company Overview
- 5.3.2.6.2 Role of Qure.AI in the Global Brain Disease Modalities and Software Market
- 5.3.2.6.3 Product Portfolio and Offerings
- 5.3.2.6.4 Recent Developments
- 5.3.2.6.5 SWOT Analysis
- 5.3.2.7 Imaging Biometrics, LLC
- 5.3.2.7.1 Company Overview
- 5.3.2.7.2 Role of Imaging Biometrics, LLC in the Global Brain Disease Modalities and Software Market
- 5.3.2.7.3 Product Portfolio and Offerings
- 5.3.2.7.4 Recent Developments
- 5.3.2.7.5 SWOT Analysis
- 5.3.2.8 A.I. Analysis, Inc.
- 5.3.2.8.1 Company Overview
- 5.3.2.8.2 Role of A.I. Analysis, Inc. in the Global Brain Disease Modalities and Software Market
- 5.3.2.8.3 Product Portfolio and Offerings
- 5.3.2.8.4 SWOT Analysis
- 6 Research Methodology
- 6.1 Data Collection and Analysis
- 6.2 Data Sources
- 6.2.1 Primary Data Sources
- 6.2.2 Secondary Data Sources
- 6.3 Data Triangulation
- 6.4 Market Estimation
- 6.5 Forecast Period Selection Criteria
- 6.6 Assumptions and Limitations
- List of Figures
- Figure 1: Global Brain Disease Modalities and Software Market, Impact Analysis
- Figure 2: Market Size Forecast (by Region), 2021 and 2031
- Figure 3: Global Brain Disease Modalities and Software Market, Overall Coverage
- Figure 4: Global Brain Disease Modalities and Software Market, Potential Forecast Scenarios
- Figure 5: Global Brain Disease Modalities and Software Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031
- Figure 6: Global Brain Disease Modalities and Software Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031
- Figure 7: Global Brain Disease Modalities and Software Market Size and Growth Potential (Pessimistic Scenario/Conservative Growth), $Million, 2020-2031
- Figure 8: Global Brain Disease Modalities and Software Market, Key Technology Trends
- Figure 9: Global Brain Disease Modalities and Software Market Key Trends, Short-Term Potential
- Figure 10: Global Brain Disease Modalities and Software Market Key Trends, Long-Term Potential
- Figure 11: Global Brain Disease Modalities and Software Market Patent Analysis (by Country/Cluster), 2018-2021
- Figure 12: Global Brain Disease Modalities and Software Market Patent Analysis (by Year), 2018-2021
- Figure 13: Global Brain Disease Modalities and Software Market, Pre-COVID-19 Phase, $Million, 2018-2031
- Figure 14: Global Brain Disease Modalities and Software Market, Impact Analysis
- Figure 15: Global Brain Disease Modalities and Software Market, Prevalence of Brain Diseases, 2010, 2015, and 2019
- Figure 16: Global Brain Disease Modalities and Software Market, Prevalence of Neurodegenerative Diseases, 2010, 2015, and 2019
- Figure 17: Global Brain Disease Modalities and Software Market, Role of AI in Medical Imaging
- Figure 18: Global Brain Disease Modalities and Software Market (by Indication)
- Figure 19: Global Brain Disease Modalities and Software Market Incremental Opportunity (by Indication), $Million, 2021-2031
- Figure 20: Global Brain Disease Modalities and Software Market, Growth Share Matrix (by Indication), 2021-2031
- Figure 21: Global Brain Disease Modalities and Software Market (Brain and Central Nervous System Cancer), $Million, 2020-2031
- Figure 22: Global Brain Disease Modalities and Software Market (Idiopathic Epilepsy), $Million, 2020-2031
- Figure 23: Global Brain Disease Modalities and Software Market (Ischemic Stroke), $Million, 2020-2031
- Figure 24: Global Brain Disease Modalities and Software Market (Other Brain Diseases), $Million, 2020-2031
- Figure 25: Global Brain Disease Modalities and Software Market (Alzheimer’s Disease), $Million, 2020-2031
- Figure 26: Global Brain Disease Modalities and Software Market (Multiple Sclerosis), $Million, 2020-2031
- Figure 27: Global Brain Disease Modalities and Software Market (Parkinson’s Disease), $Million, 2020-2031
- Figure 28: Global Brain Disease Modalities and Software Market (Motor Neuron Disease), $Million, 2020-2031
- Figure 29: Global Brain Disease Modalities and Software Market (Other Neurodegenerative Diseases), $Million, 2020-2031
- Figure 30: Global Brain Disease Modalities and Software Market (by Patient Type)
- Figure 31: Global Brain Disease Modalities and Software Market Incremental Opportunity (by Patient Type), $Million, 2021-2031
- Figure 32: Global Brain Disease Modalities and Software Market (Adults), $Million, 2020-2031
- Figure 33: Global Brain Disease Modalities and Software Market (Pediatrics and Infants), $Million, 2020-2031
- Figure 34: Global Brain Disease Modalities and Software Market (by End User)
- Figure 35: Global Brain Disease Modalities and Software Market, Incremental Opportunity (by End User), $Million, 2021-2031
- Figure 36: Global Brain Disease Modalities and Software Market (Hospitals and Clinics), $Million, 2020-2031
- Figure 37: Global Brain Disease Modalities and Software Market (Diagnostic Imaging Centers), $Million, 2020-2031
- Figure 38: Global Brain Disease Modalities and Software Market (Ambulatory Surgery Centers), $Million, 2020-2031
- Figure 39: Global Brain Disease Modalities and Software Market (by Product)
- Figure 40: Global Brain Disease Modalities and Software Market, Incremental Opportunity (by Product), $Million, 2021-2031
- Figure 41: Global Brain Disease Modalities and Software Market, Growth Share Matrix (by Product), 2021-2031
- Figure 42: Global Brain Disease Modalities and Software Market (by Brain Modalities), $Million, 2020-2031
- Figure 43: North America Brain Disease Modalities and Software Market, PET Devices, $Million, 2020-2031
- Figure 44: North America Brain Disease Modalities and Software Market, PET-CT, $Million, 2020-2031
- Figure 45: North America Brain Disease Modalities and Software Market, PET-MRI, $Million, 2020-2031
- Figure 46: North America Brain Disease Modalities and Software Market, CT Devices, $Million, 2020-2031
- Figure 47: North America Brain Disease Modalities and Software Market, MRI Devices, $Million, 2020-2031
- Figure 48: North America Brain Disease Modalities and Software Market, Brain Analysis Software, $Million, 2020-2031
- Figure 49: Global Brain Analysis Software Market, Company Revenue Share Analysis, $Million, 2021
- Figure 50: Global Brain Disease Modalities and Software Market (by Region), $Million, 2020-2031
- Figure 51: North America Brain Disease Modalities and Software Market, Incremental Revenue Opportunity (by Country), $Million, 2021-2031
- Figure 52: North America Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 53: North America Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
- Figure 54: North America Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
- Figure 55: North America Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
- Figure 56: North America Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
- Figure 57: North America Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
- Figure 58: North America Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
- Figure 59: North America Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
- Figure 60: U.S. Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 61: Canada Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 62: Europe Brain Disease Modalities and Software Market Incremental Revenue Opportunity (by Country), $Million, 2021-2031
- Figure 63: Europe Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 64: Europe Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
- Figure 65: Europe Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
- Figure 66: Europe Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
- Figure 67: Europe Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
- Figure 68: Europe Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
- Figure 69: Europe Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
- Figure 70: Europe Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
- Figure 71: Germany Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 72: U.K. Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 73: France Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 74: Italy Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 75: Spain Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 76: Rest-of-Europe Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 77: Asia-Pacific Brain Disease Modalities and Software Market, Incremental Revenue Opportunity (by Country), $Million, 2021-2031
- Figure 78: Asia-Pacific Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 79: Asia-Pacific Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
- Figure 80: Asia-Pacific Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
- Figure 81: Asia-Pacific Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
- Figure 82: Asia-Pacific Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
- Figure 83: Asia-Pacific Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
- Figure 84: Asia-Pacific Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
- Figure 85: Asia-Pacific Brain Disease Modalities and Software Market (by Country), $Million, 2021 and 2031
- Figure 86: Japan Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 87: China Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 88: India Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 89: South Korea Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 90: Australia and New Zealand Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 91: Rest-of-Asia-Pacific Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 92: Rest-of-the-World Brain Disease Modalities and Software Market Incremental Revenue Opportunity (by Country), $Million, 2021-2031
- Figure 93: Rest-of-the-World Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 94: Rest-of-the-World Brain Disease Modalities and Software Market (by Indication), $Million, 2020-2031
- Figure 95: Rest-of-the-World Brain Disease Modalities and Software Market (by Brain Diseases), $Million, 2020-2031
- Figure 96: Rest-of-the-World Brain Disease Modalities and Software Market (by Neurodegenerative Diseases), $Million, 2020-2031
- Figure 97: Rest-of-the-World Brain Disease Modalities and Software Market (by Patient Type), $Million, 2020-2031
- Figure 98: Rest-of-the-World Brain Disease Modalities and Software Market (by End User), $Million, 2020-2031
- Figure 99: Rest-of-the-World Brain Disease Modalities and Software Market (by Product), $Million, 2020-2031
- Figure 100: Rest-of-the-World Brain Disease Modalities and Software Market (by Region), $Million, 2021 and 2031
- Figure 101: Latin America Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 102: Middle East and Africa Brain Disease Modalities and Software Market, $Million, 2020-2031
- Figure 103: Partnerships, Alliances, and Business Expansions (by Company), January 2018-December 2021
- Figure 104: Funding Activities (by Company), January 2018-December 2021
- Figure 105: New Offerings (by Company), January 2018-December 2021
- Figure 106: Mergers and Acquisitions (by Company), January 2018-December 2021
- Figure 107: Mergers and Acquisitions (by Company), January 2018-December 2021
- Figure 108: Global Brain Disease Modalities and Software Market, Company Revenue Share Analysis, $Million, 2021
- Figure 109: United Imaging Healthcare Co., Ltd.: Overall Product Portfolio
- Figure 110: Koninklijke Philips N.V.: Overall Product Portfolio
- Figure 111: Koninklijke Philips N.V.: Overall Financials, $Million, 2018-2020
- Figure 112: Koninklijke Philips N.V.: Net Revenue (by Segment), $Million, 2018-2020
- Figure 113: Koninklijke Philips N.V.: Net Revenue (by Region), $Million, 2018-2020
- Figure 114: Koninklijke Philips N.V.: R&D Expenditure, $Million, 2018-2020
- Figure 115: General Electric Company: Overall Product Portfolio
- Figure 116: General Electric Company: Overall Financials, $Million, 2018-2020
- Figure 117: General Electric Company: Net Revenue (by Segment), $Million, 2018-2020
- Figure 118: General Electric Company: Net Revenue (by Region), $Million, 2018-2020
- Figure 119: General Electric Company: R&D Expenditure, $Million, 2018-2020
- Figure 120: Canon, Inc.: Overall Product Portfolio
- Figure 121: Canon, Inc.: Overall Financials, $Million, 2018-2020
- Figure 122: Canon, Inc.: Net Revenue (by Segment), $Million, 2018-2020
- Figure 123: Canon, Inc.: Revenue (by Region), $Million, 2018-2020
- Figure 124: Canon, Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 125: Siemens Healthineers AG: Overall Product Portfolio
- Figure 126: Siemens Healthineers AG: Overall Financials, $Million, 2019-2021
- Figure 127: Siemens Healthineers AG: Net Revenue (by Segment), $Million, 2019-2021
- Figure 128: Siemens Healthineers AG: Net Revenue (by Region), $Million, 2019-2021
- Figure 129: Siemens Healthineers AG: R&D Expenditure, $Million, 2019-2021
- Figure 130: Vuno Co., Ltd.: Product Portfolio
- Figure 131: Fujifilm Holdings Corporation: Product Portfolio
- Figure 132: Fujifilm Holdings Corporation: Overall Financials, $Million, 2018-2020
- Figure 133: Fujifilm Holdings Corporation: Net Revenue (by Segment), $Million, 2018-2020
- Figure 134: Fujifilm Holdings Corporation: Net Revenue (by Region), $Million, 2018-2020
- Figure 135: Fujifilm Holdings Corporation: R&D Expenditure, $Million, 2018-2020
- Figure 136: Aspect Imaging: Product Offerings
- Figure 137: IXICO: Product Portfolio
- Figure 138: IXICO: Overall Financials, $Million, 2019-2021
- Figure 139: IXICO (by Region), $Million, 2020-2021
- Figure 140: IXICO: R&D Expenditure, $Million, 2019-2021
- Figure 141: QMENTA: Product Portfolio
- Figure 142: Cortechs.ai: Product Portfolio
- Figure 143: Quantib: Product Portfolio
- Figure 144: Brainomix: Product Portfolio
- Figure 145: Qure.AI: Product Portfolio
- Figure 146: Imaging Biometrics, LLC: Product Portfolio
- Figure 147: A.I. Analysis, Inc.: Product Portfolio
- Figure 148: Global Brain Disease Modalities and Software Market: Research Methodology
- Figure 149: Primary Research
- Figure 150: Secondary Research
- Figure 151: Data Triangulation
- Figure 152: Global Brain Disease Modalities and Software Market Research Process
- Figure 153: Assumptions and Limitations
- List of Tables
- Table 1: Key Challenges and Possible Solutions for Players in the Global Brain Disease Modalities and Software Market
- Table 2: Global Brain Disease Modalities and Software Market, Quarterly Key Developments Analysis, January 2018-December 2021
- Table 3: Global Brain Disease Modalities and Software Market, Product Offerings, by Modality Types and Software
- Table 4: Global Brain Disease Modalities and Software Market, Strength of Product Offerings, by Modality Types and Software
- Table 5: Global Brain Disease Modalities and Software Market, Patient Volume of Brain Diseases
- Table 6: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Brain and Central Nervous System Cancer
- Table 7: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Idiopathic Epilepsy
- Table 8: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Ischemic Stroke
- Table 9: Global Brain Disease Modalities and Software Market, Key Modalities Analysis for Other Brain Diseases
- Table 10: Global Brain Disease Modalities and Software Market, Patient Volume of Neurodegenerative Diseases
- Table 11: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
- Table 12: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
- Table 13: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
- Table 14: Global Brain Disease Modalities and Software Market, Imaging Fee, Rest-of-the-World
- Table 15: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
- Table 16: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
- Table 17: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
- Table 18: Global Brain Disease Modalities and Software Market, Imaging Fee, Rest-of-the-World
- Table 19: Global Brain Disease Modalities and Software Market, Imaging Fee, North America
- Table 20: Global Brain Disease Modalities and Software Market, Imaging Fee, Europe
- Table 21: Global Brain Disease Modalities and Software Market, Imaging Fee, Asia-Pacific
- Table 22: Global Brain Disease Moda
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook